Overview
- The peer‑reviewed study published Monday, September 7, 2026, reported that eight weeks of CADD522 treatment in ovariectomized mice increased bone volume, preserved trabecular architecture, and reduced body weight and fat despite no change in food intake.
- CADD522 was developed as an experimental cancer agent that blocks the transcription factor RUNX2, but researchers say it is unclear why RUNX2 inhibition led to better bone formation after surgical menopause in mice.
- Analysis of brain tissue in treated mice showed reversal of several menopause‑linked shifts in fatty acids and preservation of beneficial omega‑3 levels such as DHA, suggesting wider metabolic effects beyond bone.
- Preclinical safety and pharmacokinetic work found oral tolerability in mice, rats and dogs and slower metabolism of CADD522 in human tissue samples, yet no human safety or efficacy data have been reported to date.
- If replicated in clinical trials, the finding could offer a new, repurposed approach to treat postmenopausal osteoporosis and related metabolic changes, but dose finding, safety testing and randomized efficacy trials will be required before it reaches patients.